SCHEMBL12756740

SCHEMBL12756740

COC1CCCC(C(=O)Nc2csc(-c3ccc(Br)cc3)c2C(=O)O)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 1/20 0.43
▸ SENP8 Q96LD8 1/20 0.43
▸ SENP7 Q9BQF6 1/20 0.43
▸ SENP6 Q9GZR1 1/20 0.43
▸ AAK1 Q2M2I8 1/20 0.40
▸ STK17B O94768 3/20 0.39
▸ STK17A Q9UEE5 2/20 0.36
▸ DAPK3 O43293 1/20 0.36
▸ DAPK2 Q9UIK4 1/20 0.36
▸ HDAC3 O15379 3/20 0.36
▸ HDAC1 Q13547 3/20 0.36
▸ HDAC2 Q92769 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ TNF P01375 1/20 0.34
▸ PRNP P04156 1/20 0.34
▸ NOD2 Q9HC29 1/20 0.34
▸ NOD1 Q9Y239 1/20 0.34
▸ ULK1 O75385 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12830908 0.84 HDAC1 (0.46) CASP3SENP8SENP7SENP6STK17B
SCHEMBL1954914 0.82 CASP3 (0.62) CASP3SENP8SENP7SENP6ALDH1A1
SCHEMBL12756731 0.76 CASP3 (0.39) CASP3SENP8SENP7SENP6STK17B
SCHEMBL12756734 0.76 NPY5R (0.39) CASP3SENP8SENP7SENP6HDAC3
SCHEMBL15480660 0.76 PI4KB (0.41) CASP3SENP8SENP7SENP6HDAC3
SCHEMBL12756746 0.74 EPHX2 (0.47) STK17BSTK17ADAPK3DAPK2MEN1
SCHEMBL12756748 0.74 P2RX7 (0.41) CASP3SENP8SENP7SENP6HDAC3
SCHEMBL12830039 0.72 HDAC4 (0.47) ALDH1A1SMN1; SMN2HPGDNPC1
SCHEMBL12756666 0.72 HDAC4 (0.47) ALDH1A1SMN1; SMN2HPGDNPC1
SCHEMBL12756749 0.71 TP53 (0.56) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 — — US disclosed
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 — — US disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 — — WO disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 — — US disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 CASP3 2232/4885SENP8 3756/4885SENP7 3940/4885
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 CASP3 2232/4885SENP8 3756/4885SENP7 3940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback